Insmed Inc. Stock
Price
Target price
€70.00
€70.00
2.190%
1.5
2.190%
€76.19
19.07.24 / Stuttgart Stock Exchange
WKN: A1JJA3 / Symbol: INSM / Name: Insmed / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Insmed Inc. Stock
There is an upward development for Insmed Inc. compared to yesterday, with an increase of €1.50 (2.190%).
With 42 Buy predictions and not a single Sell prediction Insmed Inc. is an absolute favorite of our community.
As a result the target price of 76 € shows a slightly positive potential of 8.57% compared to the current price of 70.0 € for Insmed Inc..
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Insmed Inc. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Insmed Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
B****
Cons
?
S********** s********
?
C******** o* t** e**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Insmed Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Insmed Inc. | 2.190% | 0.000% | 12.000% | 268.421% | 144.755% | 221.101% | 248.606% |
| Ardelyx Inc. | 0.400% | -6.042% | -11.918% | 60.952% | -12.284% | 211.043% | - |
| Evolus Inc | 1.890% | 1.887% | 10.204% | 64.885% | 19.337% | 13.089% | - |
| Coherus Bioscien. | -1.880% | -0.956% | -2.907% | -61.062% | -50.559% | -86.459% | -90.599% |
Comments
Insmed Incorporated (NASDAQ: INSM) had its price target raised by analysts at Morgan Stanley from $60.00 to $85.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for INSM provided by MarketBeat
Insmed Incorporated (NASDAQ: INSM) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $74.00 to $102.00. They now have a "buy" rating on the stock.
Show more
Ratings data for INSM provided by MarketBeat
Insmed Incorporated (NASDAQ: INSM) had its price target raised by analysts at Guggenheim from $70.00 to $95.00. They now have a "buy" rating on the stock.
Show more
Ratings data for INSM provided by MarketBeat